Given the high preponderance of KRAS activating mutations in PC (~90%), we hypothesized whether KRAS mutations could be contributing to the high frequency of Cav-1 expression in pancreatic cancer. The gene discussed is CAV1; the disease is familial pancreatic carcinoma.